Knockdown of GSG2 inhibits the development and progression of non-small cell lung cancer<i>in vitro</i>and<i>in vivo</i>
Fan Zhang(Tongji University), Jie He(First Affiliated Hospital of Jinan University), Shugeng Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Liang Zhao(Paraza Pharma (Canada)), Yibo Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Ji(Regions Hospital), Lixia Yin(Chinese Academy of Medical Sciences & Peking Union Medical College), Hao Zhang(Chinese Academy of Sciences), Qi Xue(Chinese Academy of Medical Sciences & Peking Union Medical College), Nan Sun(Hebei Medical University), Fang Lv(Liaoning Normal University), Song Peng(Chinese Academy of Medical Sciences & Peking Union Medical College), Bin Qiu(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 2
Related Papers
Cancer incidence and mortality in China, 2022
|Journal of the National Cancer Center|2024|2k
Cancer incidence and mortality in China, 2016
|Journal of the National Cancer Center|2022|1.6k
Cancer registration in China and its role in cancer prevention and control
|The Lancet Oncology|2020|501
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
|Journal of Thoracic Oncology|2020|415